免疫抑制性细胞在肝细胞癌发生发展中的作用

臧超然; 张永宏

doi:10.3969/j.issn.1001-5256.2018.07.042

免疫抑制性细胞在肝细胞癌发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2018.07.042

首都医科大学附属北京佑安医院肿瘤介入中心

基金项目:

国家自然科学基金资助项目(81320108017)；乙型肝炎与肝癌转化医学研究北京市重点实验室2016年度科技创新基地培育与发展工程子课题专项项目(Z161100005016015)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1550
- HTML全文浏览量: 35
- PDF下载量: 348
- 被引次数: 0
出版历程
- 收稿日期: 2017-12-11
- 出版日期: 2018-07-20

Role of immunosuppressive cells in the development and progression of hepatocellular carcinoma

Tumor Intervention Center, Beijing You An Hospital, Capital Medical University

Research funding:

摘要

摘要: 肝细胞癌(HCC)是全球范围内的一个重要卫生学问题,其发病率逐渐升高,且早期诊断率很低,患者出现明显的临床症状时大多已属中晚期,因而严重影响治疗效果。近年来,针对HCC的免疫治疗受到广泛关注,HCC患者疾病发生发展过程中免疫状态的变化也逐渐成为研究热点。阐述了免疫抑制性细胞在HCC发生发展过程中的作用,认为通过对免疫抑制性细胞的深入研究,将为临床HCC免疫治疗提供新的应用方向。
- 癌,肝细胞 /
- 免疫抑制性细胞 /
- 综述
Abstract: Hepatocellular carcinoma ( HCC) is a major health problem around the world. The incidence rate of HCC is gradually increasing, but its early diagnostic rate remains at a low level. Most patients who present with apparent clinical symptoms have reached the advanced stage, which greatly influences the treatment outcome. In recent years, immunotherapy for HCC has attracted more and more attention, and the change in immune status during the development and progression of HCC has gradually become a research hotspot. This article elaborates on the role of immunosuppressive cells in the development and progression of HCC and points out that in-depth studies on immunosuppressive cells will provide a new direction for immunotherapy for HCC in clinical practice.
- carcinoma, hepatocellular /
- immunosuppressive cells /
- review

HTML全文

参考文献(47)

[1]MAKAROVA-RUSHER OV, MEDINA-ECHEVERZ J, DUFFY AG, et al.The yin and yang of evasion and immune activation in HCC[J].J Hepatol, 2015, 62 (6) :1420-1429.

[2]VILLAR S, ORITZ-CUARAN S, ABEDI-ARDEKANI B, et al.Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand:Association with tumors developing in the absence of liver cirrhosis[J].PLo S One, 2012, 7 (6) :e37707.

[3] EL-SERAG HB.Hepatocellular carcinoma[J].N Engl J Med, 2011, 365 (12) :1118-1127.

[4] DIXON LJ, BARNES M, TANG H, et al.Kupffer cells in the liver[J].Compr Physiol, 2013, 3 (2) :785-797.

[5]CARAMBIA A, FREUND B, SCHWINGE D, et al.TGF-β-dependent induction of CD4+CD25+Foxp3+Tregs by liver sinusoidal endothelial cells[J].J Hepatol, 2014, 61 (3) :594-599.

[6]BOTTCHER JP, SCHANZ O, WOHLLEBER D, et al.Liverprimed memory T cells generated under noninflammatory conditions provide anti-infectious immunity[J].Cell Rep, 2013, 3 (3) :779-795.

[7]KNOLLE PA, GERMANN T, TREICHEL U, et al.Endotoxin downregulates T cell activation by antigen-presenting liver sinusoidal endothelial cells[J].J Immunol, 1999, 162 (3) :1401-1407.

[8]MUHLBAUER M, FLECK M, SCHUTZ C, et al.PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and-gamma and mediates T cell apoptosis[J].J Hepatol, 2006, 45 (4) :520-528.

[9]XIA Y, CHEN R, YE SL, et al.Inhibition of T-cell responses by intratumoral hepatic stellate cells contribute to migration and invasion of hepatocellular carcinoma[J].Clin Exp Metastasis, 2011, 28 (7) :661-674.

[10]DIEHL L, SCHURICH A, GROCHTMANN R, et al.Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+T cell tolerance[J].Hepatology, 2008, 47 (1) :296-305.

[11]KASSEL R, CRUISE MW, IEZZONI JC, et al.Chronically inflamed livers up-regulate expression of inhibitory B7 family members[J].Hepatology, 2009, 50 (5) :1625-1637.

[12]GU X, WANG Y, XIANG J, et al.Interferon-γtriggers hepatic stellate cell-mediated immune regulation through MEK/ERK signaling pathway[J].Clin Dev Immunol, 2013, 2013:389807.

[13]LI W, KUHR CS, ZHENG XX, et al.New insights into mechanisms of spontaneous liver transplant tolerance:The role of Foxp3-expressing CD25+CD4+regulatory T cells[J].Am J Transplant, 2008, 8 (8) :1639-1651.

[14]GAO HJ, ZHANG YJ, LIANG HH, et al.Radiofrequency ablation does not induce the significant increase of CD4+CD25+Foxp3+regulatory T cells compared with surgical resection in Hepal-6 tumor model[J].Arch Immunol Ther Exp (Warsz) , 2013, 61 (4) :333-340.

[15]ZHANG HH, MEI MH, FEI R, et al.Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses[J].J Viral Hepat, 2010, 17 (Suppl 1) :34-43.

[16]ZHAO HQ, LI WM, LU ZQ, et al.Roles of Tregs in development of hepatocellular carcinoma:A meta-analysis[J].World J Gastroenterol, 2014, 20 (24) :7971-7978.

[17]ORMANDY LA, HILLEMANN T, WEDEMEYER H, et al.Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma[J].Cancer Res, 2005, 65 (6) :2457-2464.

[18]UNITT E, RUSHBROOK SM, MARSHALL A, et al.Compromised lymphocytes infiltrate hepatocellular carcinoma:The role of T-regulatory cells[J].Hepatology, 2005, 41 (4) :722-730.

[19]TU JF, DING YH, YING XH, et al.Regulatory T cells, especially ICOS+FOXP3+regulatory T cells, are increased in the hepatocellular carcinoma microenvironment and predict reduced survival[J].Sci Rep, 2016, 6:35056.

[20]ZHANG HH, MEI MH, FEI R, et al.Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro[J].Int J Oncol, 2010, 36 (4) :841-848.

[21]BARRA MM, RICHARDS DM, HOFER AC, et al.Premature expression of Foxp3 in double-negative thymocytes[J].PLo S One, 2015, 10 (5) :e0127038.

[22]BEYER M, CLASSEN S, ENDL E, et al.Comparative approach to define increased regulatory T cells in different cancer subtypes by combined assessment of CD127 and FOXP3[J].Clin Dev Immunol, 2011, 2011:734036.

[23]KAKITA N, KANTO T, ITOSE I, et al.Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma:A crucial role of CD25-FOXP3-T cells[J].Int J Cancer, 2012, 131 (11) :2573-2583.

[24]HAO WB, XIANG FF, LIU QL, et al.Research advances of myeloid inhibitory cells in tumor microenvironment[J].Immunol J, 2017, 33 (8) :729-732. (in Chinese) 郝文斌, 相芬芬, 刘巧丽, 等.髓源抑制细胞在肿瘤微环境中的研究进展[J].免疫学杂志, 2017, 33 (8) :729-732.

[25]HAILE LA, GAMREKELASHVILI J, MANNS MP, et al.CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice[J].J Immunol, 2010, 185 (1) :203-210.

[26]HOECHST B, ORMANDY LA, BALLMAIER M, et al.A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+T cells[J].Gastroenterology, 2008, 135 (1) :234-243.

[27]CHIU DK, XU IM, LAI RK, et al.Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26[J].Hepatology, 2016, 64 (3) :797-813.

[28]XU Y, ZHAO W, XU J, et al.Activated hepatic stellate cells promote liver cancer by induction of myeloid-derived suppressor cells through cyclooxygenase-2[J].Oncotarget, 2016, 7 (8) :8866-8878.

[29]KAPANADZE T, GAMREKELASHVILI J, MA C, et al.Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma[J].J Hepatol, 2013, 59 (5) :1007-1013.

[30]DENG Y, CHENG J, FU B, et al.Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells[J].Oncogene, 2017, 36 (8) :1090-1101.

[31]SICA A, MANTOVANI A.Macrophage plasticity and polarization:In vivo veritas[J].J Clin Invest, 2012, 122 (3) :787-795.

[32]BISWAS SK, MANTOVANI A.Macrophage plasticity and interaction with lymphocyte subsets:Cancer as a paradigm[J].Nat Immunol, 2010, 11 (10) :889-896.

[33]JEANNIN P, PAOLINI L, ADAM C, et al.The roles of CSFs on the functional polarization of tumor-associated macrophages[J].FEBS J, 2018, 285 (4) :680-699.

[34]SAWA-WEJKSZA K, KANDEFER-SZERSZEN'M.Tumor-associated macrophages as target for antitumor therapy[J].Arch Immunol Ther Exp (Warsz) , 2018, 66 (2) :97-111.

[35] GABRILOVICH DI, NAQARAJ S.Myeloid-derived suppressor cells as regulators of the immune system[J].Nat Rev Immunol, 2009, 9 (3) :162-174.

[36]TAKAI H, HATO A, KATO C, et al.The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma[J].Liver Int, 2009, 29 (7) :1056-1064.

[37]WAN S, ZHAO E, KRYCZEK I, et al.Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells[J].Gastroenterology, 2014, 147 (6) :1393-1404.

[38]MANO Y, AISHIMA S, FUJITA N, et al.Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma[J].Pathobiology, 2013, 80 (3) :146-154.

[39]YANG W, LU Y, XU Y, et al.Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs) [J].J Biol Chem, 2012, 287 (48) :40140-40149.

[40]NAUGLER WE, SAKURAI T, KIM S, et al.Gender disparity in liver cancer due to sex differences in My D88-dependent IL-6 production[J].Science, 2007, 317 (5834) :121-124.

[41]DENG YR, LIU WB, LIAN ZX, et al.Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma[J].Oncotarget, 2016, 7 (25) :38292-38305.

[42]YANG H, ZHANG S, XIN YF.Research progress on immunotherapy in treating cancer[J].Chin J Clin Pharmacol Ther, 2016, 21 (9) :1074-1080. (in Chinese) 杨何, 张升, 辛艳飞.肿瘤免疫治疗研究进展[J].中国临床药理学与治疗学, 2016, 21 (9) :1074-1080.

[43]HAN Y, CHEN Z, YANG Y, et al.Human CD14+CTLA-4+regulatory dendritic cells suppress T-cell response by cytotoxic Tlymphocyte antigen-4-dependent IL-10 and indoleamine-2, 3-dioxygenase production in hepatocellular carcinoma[J].Hepatology 2014, 59 (2) :567-579.

[44]CHU CC, ALI N, KARAGIANNIS P, et al.Resident CD141 (BDCA3) +dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation[J].J Exp Med, 2012, 209 (5) :935-945.

[45]WU P, WU D, LI L, et al.PD-L1 and survival in solid tumors:A meta-analysis[J].PLo S One, 2015, 10 (6) :e0131403.

[46]NAKAMOTO N, CHO H, SHAKED A, et al.Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade[J].PLo S Pathog, 2009, 5 (2) :e1000313.

[47]NAKAMOTO N, KAPLAN DE, COLECLOUGH J, et al.Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization[J].Gastroenterology, 2008, 134 (7) :1927-1937.

施引文献

资源附件(0)

访问统计